Lead Product(s) : Relutrigine
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRAX-562 is a first selective persistent sodium current blocker. Praxis plans to initiate a Phase 2 clinical trial in the first half of 2022 to explore the potential for PRAX-562 to treat a range of rare pediatric DEEs, including SCN2A-DEE and SCN8A-DEE.
Product Name : PRAX-562
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Relutrigine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable